Latest Breaking News On - Thomas duthy - Page 1 : comparemela.com

Why these ASX firms are shying away from the pot stock label – Part 2

Why these ASX firms are shying away from the pot stock label – Part 2
theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.

Jo pattersonThomas duthyBynadine mcgrathWhile neurotech internationalJazz pharmaceuticalsAustralian registerTherapeutic goodsLennox gastaut syndromeDravet syndromeTuberous sclerosisBio absorbNeurotech international

ASX cannabis stocks making almighty push for approval with clinical trials

ASX cannabis stocks making almighty push for approval with clinical trials
theaustralian.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theaustralian.com.au Daily Mail and Mail on Sunday newspapers.

Jo pattersonBynadine mcgrathMichael winloThomas duthyJoel lathamEmperor shen nungRoby zomerArcadia pharmaceuticalsDrug administrationProcaps group united statesNeuren pharmaceuticalsAustralia therapeutic goods administrationGetty imagesTherapeutic goods administrationAustralian registerTherapeutic goods

Dr Boreham s Crucible: Arovella Therapeutics

Dr Boreham s Crucible: Arovella Therapeutics
fnarena.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fnarena.com Daily Mail and Mail on Sunday newspapers.

United statesCity ofUnited kingdomWestern australiaDebora bartonElizabeth stonerSuda arovellaImugene oncarlyticsTom duthyPaul hopperRadiopharm theranosticsStephen carterDavid simmondsGary phillipsHarpic flushmaticTim boreham

Neurotech International to launch clinical program into use of lead drug NTI164 to treat Rett Syndrome

Clinical-stage biopharmaceutical development company Neurotech International (ASX: NTI) has launched a new clinical program into the use of daily oral cannabinoid-based drug to potentially treat Rett Syndrome in female patients.

South australiaThomas duthyNeurotech internationalPaediatric neurology unit at monash medical centreAustralia therapeutic goods administrationDepartment of neurodevelopment disabilityRett syndrome researchRett syndromeRoyal childrenPaediatric neurology unitMonash medicalClinical trial notificationTherapeutic goods administrationRett syndrome research trust

Arovella Therapeutics Ltd recruits biotech stalwart as non-executive chair

Arovella Therapeutics Ltd (ASX:ALA) has welcomed medtech stalwart Dr Thomas Duthy as its next non-executive chair. The incoming executive will take the.

Michael bakerElizabeth stonerThomas duthyImugene ltdInvex therapeutics ltdArovella therapeutics ltdNemean groupNeurotech international ltdNova eye medicalSirtex medical